FindMyKOL
Clinical trialNCT00811590TerminatedPhase 2Interventional

Pilot Study of mTOR Inhibitor Therapy in Peutz-Jeghers Syndrome

NCT00811590 is a phase 2 interventional trial sponsored by University of Utah. As of 21 Nov 2026, it was terminated. It studies Everolimus in Peutz-Jeghers Syndrome. The registry lists an enrollment of 3 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2008 and a primary completion date of 31 Mar 2011.

SponsorUniversity of Utah →Enrollment3Peutz-Jeghers Syndrome
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00811590
FieldValue
Registry IDNCT00811590
StatusTerminated
PhasePhase 2
Study typeInterventional trial
Lead sponsorUniversity of Utah
Enrollment3
Registered sites1
Countries1
ConditionsPeutz-Jeghers Syndrome
DrugsEverolimus
Start30 Nov 2008
Primary completion31 Mar 2011
Study completion31 Mar 2011
Last update posted19 Sept 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Pilot study, Open-label, Phase II study of Everolimus. Objective: To determine if Everolimus can diminish large gastrointestinal polyps in patients with Peutz-Jeghers Syndrome. Methodology: Polyp size and number will be compared to baseline by FDG-PET and CT and 12 months after treatment with Everolimus. Since this is a pilot study, the polyps prior to treatment will serve as the controls.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Utah, United States1 site
  • Huntsman Cancer Institute

    Salt Lake City

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtah: 1 siteUT1ColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00811590

Each answer restates registry values shown on this page.

What is NCT00811590?

NCT00811590 is a phase 2 interventional trial sponsored by University of Utah. It studies Everolimus in Peutz-Jeghers Syndrome.

Who leads NCT00811590?

The registry names Randall W Burt, MD (principal investigator, Huntsman Cancer Institute) and Scott Kuwada, MD (study chair, University of Hawaii) as overall officials.

Where does NCT00811590 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00811590 study?

The registered drug and biological interventions are Everolimus.

When did NCT00811590 end?

The registry lists a primary completion date of 31 Mar 2011 and a study completion date of 31 Mar 2011. The sponsor last updated the record on 19 Sept 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.